156 related articles for article (PubMed ID: 27136372)
1. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
[TBL] [Abstract][Full Text] [Related]
3. An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
Perrone MG; Miciaccia M; Vitale P; Ferorelli S; Araújo CDCB; de Almeida GS; Souza Domingos TF; da Silva LCRP; de Pádula M; Cabral LM; Sathler PC; Bonaccorso C; Fortuna CG; Scilimati A
Eur J Med Chem; 2021 Jan; 209():112919. PubMed ID: 33129592
[TBL] [Abstract][Full Text] [Related]
4. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A
Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965
[TBL] [Abstract][Full Text] [Related]
6. Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.
Estevão MS; Carvalho LC; Freitas M; Gomes A; Viegas A; Manso J; Erhardt S; Fernandes E; Cabrita EJ; Marques MM
Eur J Med Chem; 2012 Aug; 54():823-33. PubMed ID: 22796043
[TBL] [Abstract][Full Text] [Related]
7. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.
El-Achkar GA; Jouni M; Mrad MF; Hirz T; El Hachem N; Khalaf A; Hammoud S; Fayyad-Kazan H; Eid AA; Badran B; Merhi RA; Hachem A; Hamade E; Habib A
Eur J Pharmacol; 2015 Mar; 750():66-73. PubMed ID: 25617797
[TBL] [Abstract][Full Text] [Related]
8. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
Vitale P; Perrone MG; Malerba P; Lavecchia A; Scilimati A
Eur J Med Chem; 2014 Mar; 74():606-18. PubMed ID: 24531199
[TBL] [Abstract][Full Text] [Related]
9. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Pati ML; Vitale P; Ferorelli S; Iaselli M; Miciaccia M; Boccarelli A; Di Mauro GD; Fortuna CG; Souza Domingos TF; Rodrigues Pereira da Silva LC; de Pádula M; Cabral LM; Sathler PC; Vacca A; Scilimati A; Perrone MG
Eur J Med Chem; 2019 Feb; 164():59-76. PubMed ID: 30590258
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors.
Zanatta SD; Manallack DT; Jarrott B; Williams SJ
Bioorg Med Chem Lett; 2009 Jan; 19(2):459-61. PubMed ID: 19056264
[TBL] [Abstract][Full Text] [Related]
11. A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior.
Solidoro R; Miciaccia M; Bonaccorso C; Fortuna CG; Armenise D; Centonze A; Ferorelli S; Vitale P; Rodrigues P; Guimarães R; de Oliveira A; da Paz M; Rangel L; Sathler PC; Altomare A; Perrone MG; Scilimati A
Eur J Med Chem; 2024 Feb; 266():116135. PubMed ID: 38219659
[TBL] [Abstract][Full Text] [Related]
12. Syntheses and characterization of nimesulide derivatives for dual enzyme inhibitors of both cyclooxygenase-1/2 and 5-lipoxygenase.
Li Y; Chen SH; Ou TM; Tan JH; Li D; Gu LQ; Huang ZS
Bioorg Med Chem; 2011 Mar; 19(6):2074-83. PubMed ID: 21349729
[TBL] [Abstract][Full Text] [Related]
13. Targeting COX-1 by mofezolac-based fluorescent probes for ovarian cancer detection.
Scilimati A; Ferorelli S; Iaselli MC; Miciaccia M; Pati ML; Fortuna CG; Aleem AM; Marnett LJ; Perrone MG
Eur J Med Chem; 2019 Oct; 179():16-25. PubMed ID: 31229884
[TBL] [Abstract][Full Text] [Related]
14. Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors.
Shi L; Li ZL; Yang Y; Zhu ZW; Zhu HL
Bioorg Med Chem Lett; 2011 Jan; 21(1):121-4. PubMed ID: 21144750
[TBL] [Abstract][Full Text] [Related]
15. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model.
Perrone MG; Vitale P; Panella A; Fortuna CG; Scilimati A
Eur J Med Chem; 2015 Apr; 94():252-64. PubMed ID: 25768707
[TBL] [Abstract][Full Text] [Related]
16. Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations.
Mohassab AM; Hassan HA; Abdelhamid D; Abdel-Aziz M; Dalby KN; Kaoud TS
Bioorg Chem; 2017 Dec; 75():242-259. PubMed ID: 29032325
[TBL] [Abstract][Full Text] [Related]
17. Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling.
Hawash M; Abdallah S; Abudayyak M; Melhem Y; Abu Shamat M; Aghbar M; Çapan I; Abualhasan M; Kumar A; Kamiński M; Góral T; Dominiak PM; Sobuh S
Eur J Med Chem; 2024 May; 271():116397. PubMed ID: 38626522
[TBL] [Abstract][Full Text] [Related]
18. Dual evaluation of some novel 2-amino-substituted coumarinylthiazoles as anti-inflammatory-antimicrobial agents and their docking studies with COX-1/COX-2 active sites.
Chandak N; Kumar P; Kaushik P; Varshney P; Sharma C; Kaushik D; Jain S; Aneja KR; Sharma PK
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):476-84. PubMed ID: 23777557
[TBL] [Abstract][Full Text] [Related]
19. Molecular Docking of Bioactive Compounds Against BRCA and COX Proteins.
Prog Drug Res; 2016; 71():181-3. PubMed ID: 26939289
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new 4-phenylpyrimidine-2(1H)-thiones and their potency to inhibit COX-1 and COX-2.
Seebacher W; Faist J; Presser A; Weis R; Saf R; Kaserer T; Temml V; Schuster D; Ortmann S; Otto N; Bauer R
Eur J Med Chem; 2015 Aug; 101():552-9. PubMed ID: 26197159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
